Utility of WHOQOL-BREF in measuring quality of life in sickle cell disease

Monika R Asnani, Garth E Lipps, Marvin E Reid, Monika R Asnani, Garth E Lipps, Marvin E Reid

Abstract

Background: Sickle cell disease is the commonest genetic disorder in Jamaica and most likely exerts numerous effects on quality of life (QOL) of those afflicted with it. The WHOQOL-Bref, which is a commonly utilized generic measure of quality of life, has never previously been utilized in this population. We have sought to study its utility in this disease population.

Methods: 491 patients with sickle cell disease were administered the questionnaire including demographics, WHOQOL-Bref, Short Form-36 (SF-36), Flanagan's quality of life scale (QOLS) and measures of disease severity at their routine health maintenance visits to the sickle cell unit. Internal consistency reliabilities, construct validity and "known groups" validity of the WHOQOL-Bref, and its domains, were examined; and then compared to those of the other instruments.

Results: All three instruments had good internal consistency, ranging from 0.70 to 0.93 for the WHOQOL-Bref (except the 'social relationships' domain), 0.86-0.93 for the SF-36 and 0.88 for the QOLS. None of the instruments showed any marked floor or ceiling effects except the SF-36 'physical health' and 'role limitations' domains. The WHOQOL-Bref scale also had moderate concurrent validity and showed strong "known groups" validity.

Conclusion: This study has shown good psychometric properties of the WHOQOL-Bref instrument in determining QOL of those with sickle cell disease. Its utility in this regard is comparable to that of the SF-36 and QOLS.

References

    1. Serjeant GR, Serjeant BE. Sickle Cell Disease. Third. Oxford: Oxford University Press; 2001.
    1. McCaw-Binns A, Alexander SF, Lindo JL, Escoffery C, Spence K, Lewis-Bell K, Lewis G. Epidemiologic transition in maternal mortality and morbidity: new challenges for Jamaica. Int J Gynaecol Obstet. 2007;96:226–232. doi: 10.1016/j.ijgo.2006.12.002.
    1. Barton EN, Sargeant LA, Samuels D, Smith R, James J, Wilson R, Smith F, Falconer H, Yeates C, Smikle MF, et al. A survey of chronic renal failure in Jamaica. West Indian Med J. 2004;53:81–84.
    1. Escoffery CT, Shirley SE. Causes of sudden natural death in Jamaica: a medicolegal (coroner's) autopsy study from the University Hospital of the West Indies. Forensic Sci Int. 2002;129:116–121. doi: 10.1016/S0379-0738(02)00268-2.
    1. Wierenga KJ, Hambleton IR, Lewis NA. Survival estimates for patients with homozygous sickle-cell disease in Jamaica: a clinic-based population study. Lancet. 2001;357:680–683. doi: 10.1016/S0140-6736(00)04132-5.
    1. Wison Schaeffer JJ, Gil KM, Burchinal M, Kramer KD, Nash KB, Orringer E, Strayhorn D. Depression, disease severity, and sickle cell disease. J Behav Med. 1999;22:115–126. doi: 10.1023/A:1018755831101.
    1. Ohaeri JU, Shokunbi WA, Akinlade KS, Dare LO. The psychosocial problems of sickle cell disease sufferers and their methods of coping. Soc Sci Med. 1995;40:955–960. doi: 10.1016/0277-9536(94)00154-L.
    1. Jacob E. The pain experience of patients with sickle cell anemia. Pain Manag Nurs. 2001;2:74–83. doi: 10.1053/jpmn.2001.26119.
    1. Anie KA, Steptoe A, Bevan DH. Sickle cell disease: Pain, coping and quality of life in a study of adults in the UK. Br J Health Psychol. 2002;7:331–344. doi: 10.1348/135910702760213715.
    1. Anie KA, Steptoe A. Pain, mood and opioid medication use in sickle cell disease. Hematol J. 2003;4:71–73. doi: 10.1038/sj.thj.6200227.
    1. Bodhise PB, Dejoie M, Brandon Z, Simpkins S, Ballas SK. Non-pharmacologic Management of Sickle Cell Pain. Hematology. 2004;9:235–237. doi: 10.1080/10245330410001701495.
    1. Strickland OL, Jackson G, Gilead M, McGuire DB, Quarles S. Use of focus groups for pain and quality of life assessment in adults with sickle cell disease. J Natl Black Nurses Assoc. 2001;12:36–43.
    1. Kater AP, Heijboer H, Peters M, Vogels T, Prins MH, Heymans HS. [Quality of life in children with sickle cell disease in Amsterdam area] Ned Tijdschr Geneeskd. 1999;143:2049–2053.
    1. Thomas VJ, Taylor LM. The psychosocial experience of people with sickle cell disease and its impact on quality of life: Qualitative findings from focus groups. Br J Health Psychol. 2002;7:345–363. doi: 10.1348/135910702760213724.
    1. Anie KA. Psychological complications in sickle cell disease. Br J Haematol. 2005;129:723–729. doi: 10.1111/j.1365-2141.2005.05500.x.
    1. Maxwell K, Streetly A, Bevan D. Experiences of hospital care and treatment seeking for pain from sickle cell disease: qualitative study. Bmj. 1999;318:1585–1590.
    1. Midence K, Fuggle P, Davies SC. Psychosocial aspects of sickle cell disease (SCD) in childhood and adolescence: a review. Br J Clin Psychol. 1993;32:271–280.
    1. Asnani M. The Prevalence of Depression in Sickle Cell Disease in the Jamaican Cohort. Kingston, Jamaica.: University of the West Indies; 2004.
    1. Brown RT, Kaslow NJ, Doepke K, Buchanan I, Eckman J, Baldwin K, Goonan B. Psychosocial and family functioning in children with sickle cell syndrome and their mothers. J Am Acad Child Adolesc Psychiatry. 1993;32:545–553.
    1. Gil KM, Abrams MR, Phillips G, Keefe FJ. Sickle cell disease pain: relation of coping strategies to adjustment. J Consult Clin Psychol. 1989;57:725–731. doi: 10.1037/0022-006X.57.6.725.
    1. Hasan SP, Hashmi S, Alhassen M, Lawson W, Castro O. Depression in sickle cell disease. J Natl Med Assoc. 2003;95:533–537.
    1. Thomas VJ, Hambleton I, Serjeant G. Psychological distress and coping in sickle cell disease: comparison of British and Jamaican attitudes. Ethn Health. 2001;6:129–136. doi: 10.1080/13557850120068450.
    1. McClish DK, Penberthy LT, Bovbjerg VE, Roberts JD, Aisiku IP, Levenson JL, Roseff SD, Smith WR. Health related quality of life in sickle cell patients: The PiSCES project. Health Qual Life Outcomes. 2005;3:50. doi: 10.1186/1477-7525-3-50.
    1. Asnani M, Lipps G, Reid M. Validation of the SF-36 in Jamaicans with Sickle Cell Disease. Psychology, Health & Medicine (accepted for publication April 2009)
    1. WHOQOL Group The World Health Organization Quality of Life Assessment: development and general psychometric properties. Soc Sci Med. 1998;46:1569–1585. doi: 10.1016/S0277-9536(98)00009-4.
    1. WHOQOL Group Development of the World Health Organization WHOQOL-BREF quality of life assessment. Psychol Med. 1998;28:551–558. doi: 10.1017/S0033291798006667.
    1. Liang WM, Chen JJ, Chang CH, Chen HW, Chen SL, Hang LW, Wang JD. An empirical comparison of the WHOQOL-BREF and the SGRQ among patients with COPD. Qual Life Res. 2008;17:793–800. doi: 10.1007/s11136-008-9326-5.
    1. Skevington SM. Advancing cross-cultural research on quality of life: observations drawn from the WHOQOL development. World Health Organisation Quality of Life Assessment. Qual Life Res. 2002;11:135–144. doi: 10.1023/A:1015013312456.
    1. Sherlock P, Bennete H. The story of the Jamaican people. Kingston, Jamaica: Ian Randle Publishers; 2000.
    1. Burckhardt CS, Anderson KL. The Quality of Life Scale (QOLS): Reliability, Validity, and Utilization. Health Qual Life Outcomes. 2003;1:60. doi: 10.1186/1477-7525-1-60.
    1. United Nations Development Programme Human Development Report, Jamaica. 2008.
    1. Skevington SM, Lotfy M, O'Connell KA. The World Health Organization's WHOQOL-BREF quality of life assessment: psychometric properties and results of the international field trial. A report from the WHOQOL group. Qual Life Res. 2004;13:299–310. doi: 10.1023/B:QURE.0000018486.91360.00.
    1. Asnani M, Lipps G, Reid M. Component structure of the SF-36 in Jamaicans with Sickle Cell Disease. West Indian Medical Journal. 2007;56:491–497.
    1. Flanagan JC. Measurement of quality of life: current state of the art. Arch Phys Med Rehabil. 1982;63:56–59.
    1. StataCorp . Stata 8.2. 4905 Lakeway Drive, College Station, Texas 77845 USA; 1984.
    1. WHOQOL Group Introduction, administration, scoring and generic version of the assessment- field trial version. 1996.
    1. Bland JM, Altman DG. Cronbach's alpha. Bmj. 1997;314:572.
    1. Smith WR, Bovbjerg VE, Penberthy LT, McClish DK, Levenson JL, Roberts JD, Gil K, Roseff SD, Aisiku IP. Understanding pain and improving management of sickle cell disease: the PiSCES study. J Natl Med Assoc. 2005;97:183–193.
    1. Smith WR, Penberthy LT, Bovbjerg VE, McClish DK, Roberts JD, Dahman B, Aisiku IP, Levenson JL, Roseff SD. Daily assessment of pain in adults with sickle cell disease. Ann Intern Med. 2008;148:94–101.
    1. Stuart MJ, Nagel RL. Sickle-cell disease. Lancet. 2004;364:1343–1360. doi: 10.1016/S0140-6736(04)17192-4.
    1. Unalan D, Soyuer F, Ozturk A, Mistik S. Comparison of SF-36 and WHOQOL-100 in patients with stroke. Neurol India. 2008;56:426–432. doi: 10.4103/0028-3886.44573.
    1. Baum KF, Dunn DT, Maude GH, Serjeant GR. The painful crisis of homozygous sickle cell disease. A study of the risk factors. Arch Intern Med. 1987;147:1231–1234. doi: 10.1001/archinte.147.7.1231.
    1. Rees DC, Olujohungbe AD, Parker NE, Stephens AD, Telfer P, Wright J. Guidelines for the management of the acute painful crisis in sickle cell disease. Br J Haematol. 2003;120:744–752. doi: 10.1046/j.1365-2141.2003.04193.x.
    1. Serjeant GR. The dilemma of defining clinical severity in homozygous sickle cell disease. Curr Hematol Rep. 2004;3:307–309.
    1. Solomon LR. Treatment and prevention of pain due to vaso-occlusive crises in adults with sickle cell disease: an educational void. Blood. 2008;111:997–1003. doi: 10.1182/blood-2007-07-089144.
    1. Skevington SM. Investigating the relationship between pain and discomfort and quality of life, using the WHOQOL. Pain. 1998;76:395–406. doi: 10.1016/S0304-3959(98)00072-4.
    1. Kato GJ, McGowan V, Machado RF, Little JA, Taylor Jt, Morris CR, Nichols JS, Wang X, Poljakovic M, Morris SM, Jr, et al. Lactate dehydrogenase as a biomarker of hemolysis-associated nitric oxide resistance, priapism, leg ulceration, pulmonary hypertension, and death in patients with sickle cell disease. Blood. 2006;107:2279–2285. doi: 10.1182/blood-2005-06-2373.
    1. Steinberg MH. Predicting clinical severity in sickle cell anaemia. Br J Haematol. 2005;129:465–481. doi: 10.1111/j.1365-2141.2005.05411.x.
    1. Cumming V, King L, Fraser R, Serjeant G, Reid M. Venous incompetence, poverty and lactate dehydrogenase in Jamaica are important predictors of leg ulceration in sickle cell anaemia. Br J Haematol. 2008;142:119–125. doi: 10.1111/j.1365-2141.2008.07115.x.

Source: PubMed

Sponsorer och medarbetare

Medicinska tillstånd

Läkemedelsinterventioner

3
Prenumerera